Table 1.

The development program of main JAK inhibitors.

JAK inhibitor	JAK selectivity	Disease	Clinical status
Baricitinib	1,2	RA Atopic Dermatitis Alopecia SLE JIA Psoriasis Giant cell arteritis	Approved (EMA, FDA) Phase III Phase III Phase III Phase III Phase II Phase II
Tofacitinib	3,1,2	RA SpA Psoriasis JIA SLE CD UC Alopecia areata Uveitis, scleritis SLE, DLE Dermatomyositis Systemic sclerosis	Approved (EMA, FDA) Phase IV Phase III Phase III Phase II Phase II Phase III Phase IV Phase II Phase II Phase I Phase I
Upadacitinib	1	RA PsA AS UC AD CD Giant cell arteritis Pediatric AD JIA	Approved FDA, submitted EMA Phase III Phase II Phase III Phase III Phase III Phase III Phase I Phase I
Filgotinib	1	RA AS PsA UC CD Small bowel CD Fistulizing CD Sjögren syndrome Cutaneous lupus Lupus nephropathy Uveitis	Phase III Phase II Phase II Phase III Phase III Phase II Phase II Phase II Phase II Phase II Phase II

AD, atopic dermatitis; CD, Crohn’s disease; DLE, discoid lupus erythematosus; EMA, European Medicine Agency; FDA, Food and Drug Administration; JAK, Janus kinase; JIA, juvenile idiopathic arthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SpA, spondyloarthritis; UC, ulcerative colitis.